AstraZeneca Acquires Innate Pharma's NKG2A Antibody for $825M, Xinjiang Launches First Internet Hospital, and Sichuan Deploys First 'Robo-Nurse'

What is the current state of the information security market in the healthcare industry? What are the prevailing vulnerabilities in hospital information security? How should hospitals address information security challenges posed by innovative digital health products and the escalating threat of ransomware? These questions will be explored in depth in this article.

What impacts will the development of “Internet + Healthcare” have on pharmaceutical distribution and retail? What are the characteristics of internet marketing models and pharmaceutical e-commerce channels? How can pharmaceutical companies leverage innovative marketing strategies to achieve growth, and where do the lucrative opportunities lie? VCBeat will analyze industry changes by focusing on the OTC drug market.

Among entrepreneurs in the gene sequencing sector, some are beginning to integrate the concept of “precision” into fitness. It is predicted that this market alone could reach a scale of tens of billions of yuan in China. VCBeat has reviewed several foreign products and their business models to examine how they operate.

To comprehensively present Zhejiang’s “At Most One Visit” healthcare reform from multiple perspectives, VCBeat conducted multi-faceted interviews at the “4th Zhejiang International Health Industry Expo” in Hangzhou.

Ma Weihang, Deputy Director of the Zhejiang Provincial Health Commission; Zhu Yanfeng, Deputy Director of the Hangzhou Municipal Health Commission; Zhang Weiqing, Director of the Taizhou Municipal Health Commission; Zheng Yunzheng, Director of the Medical Administration Division of the Wenzhou Municipal Health Commission; Ding Kefeng, Vice President of the Second Affiliated Hospital of Zhejiang University School of Medicine; and Zhou Mengtao, President of the First Affiliated Hospital of Wenzhou Medical University, respectively shared their perspectives on the progress made and the challenges encountered in advancing the “At Most One Visit” initiative for healthcare services.

StartUp Health has unveiled six major trends in global digital health financing and investment—such as the continuous rise in transaction values and volumes, with China leading the international market—by analyzing publicly available data on seed, venture capital, and private equity investments. The report also presents a top ranking of digital health deals, offering analyses by region and sub-sector. VCBeat has promptly compiled and translated this report.

The First Generic Application for the “Most Potent Hepatitis B Drug” in History Submitted for Market Approval

On October 22, the Center for Drug Evaluation (CDE) accepted Chia Tai Tianqing’s marketing application for a generic version of Tenofovir Alafenamide (TAF) tablets, marking another breakthrough for Chia Tai Tianqing, known as the “King of First Generics.” TAF, developed by Gilead Sciences, is indicated for the treatment of patients with chronic hepatitis B (HBV) infection accompanied by compensated liver disease. The originator product has not yet been launched in China.

Hisun Pharma Targets the European Market! Celecoxib API Awarded CEP Certificate

On the evening of October 23, Hisun Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Hisun Pharmaceutical (Nantong) Co., Ltd. (hereinafter referred to as “Hisun Nantong”), had received a Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP Certificate) for celecoxib active pharmaceutical ingredient (API), issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Additionally, on the previous evening, Hisun Pharmaceutical also announced that the Abbreviated New Drug Application (ANDA) for capreomycin for injection, submitted to the U.S. Food and Drug Administration (FDA) by its controlled subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd., had been approved.

AstraZeneca Acquires Innate Immune Therapy Assets for $825 Million

On October 24, AstraZeneca announced that it would acquire the NKG2A antibody monalizumab from French biotechnology company Innate Pharma SA for an upfront payment of $100 million. An additional $100 million will be paid if the drug enters Phase III clinical trials, with total milestone payments reaching up to $825 million. AstraZeneca will be responsible for 70% of late-stage development, while Innate Pharma will handle the remaining 30%.

Yunnan Launches First Internet Hospital to Alleviate "Difficulty in Accessing Medical Care" for Grassroots Populations

On October 23, patients can book appointments via an online platform, consult with doctors in real time, and purchase medications offline or be admitted to a nearby hospital based on the electronic prescriptions and hospitalization certificates issued by the physicians. The Internet Hospital of Yunnan Cancer Hospital was officially launched and began operations on the 22nd, marking the first internet hospital in Yunnan Province built upon a physical hospital.

BD China’s Localization Strategy Gains Momentum, Accelerating Its Grab of the Chinese Market

On October 24, BD Medical, a global leader in medical technology, formed a strategic partnership with Sinopharm Group, the leading pharmaceutical distributor in China. The two parties will jointly promote extensive cooperation in the field of medical products and services in China.

Supporting Birth Defect Prevention and Early Intervention for Rare Diseases, Mingma Biotech Partners with Fudan Children’s Hospital to Launch Newborn Screening Products

On October 26, during the “Xin Sheng, Love One Step Earlier” launch event for a newborn genetic screening product held in conjunction with the 23rd National Pediatric Academic Conference of the Chinese Medical Association, BGI Genomics (Shanghai) Biotechnology Co., Ltd., a global leader in precision medicine and an integrated platform for gene R&D, application, and big data empowerment, announced in partnership with the Children’s Hospital of Fudan University that they would jointly launch a new newborn genetic screening product named “Xin Ma.”

Sichuan’s First “Robot Nurse” Goes Online

On October 24, Sichuan’s first “robot nurse” officially began its duties at the Sichuan Provincial People’s Hospital. By utilizing robotic arms to rapidly and precisely prepare chemotherapy medications for cancer patients, it has not only improved medication preparation efficiency and accuracy but also reduced the risk of occupational hazards for healthcare workers.

Beijing Children’s Hospital Partners with 999 Emergency Center to Open New Lifelines for Young Patients

On October 23, Beijing Children’s Hospital and the 999 Emergency Medical Center signed a strategic cooperation agreement. This collaboration will establish a new lifeline for the transport of critically ill neonates within the national pediatric medical consortium, holding significant importance for the comprehensive development of the referral and consultation network for critically ill neonates and the further standardization of related referral and consultation practices.

Xinjiang’s First Internet Hospital Established

On October 26, the Jianke Internet Hospital project at Tumxuk City People’s Hospital was officially launched in Tumxuk, Xinjiang. The Health Bureau of Tumxuk City, Third Division of the Xinjiang Production and Construction Corps, issued the “Medical Institution Practice License” to the Jianke Internet Hospital of Tumxuk City People’s Hospital. This marks the first medical institution in Xinjiang to obtain an internet hospital practice license, signifying the formal establishment of Xinjiang’s first internet hospital on that day.

This week, there were a total of 22 financing events in the medical sector both domestically and internationally.

I believe that over the next 5 to 18 years, investment opportunities in China’s pharmaceutical industry will center on two strategic directions encapsulated in eight Chinese characters: first, investing in R&D innovation by partnering with early-stage scientists and innovative teams; and second, pursuing mergers and acquisitions (M&A) and consolidation. Regardless of whether we look at industry, commerce, or services, or whether we consider medical devices, pharmaceuticals, or hospitals, China lacks truly mega-sized enterprises. The healthcare sector remains fragmented, scattered, and disorganized, presenting substantial M&A opportunities. Over the past three years, Chinese companies have actively engaged in cross-border M&A: deal volume stood at only USD 1 billion in 2015 but surpassed USD 4 billion by 2017. I anticipate this trend will become even more pronounced in the future. As the secondary market continues to expand, opportunities for cross-border arbitrage will persist, particularly those driven by technology and industrial consolidation. (Source: Pedaily)

On October 23, wearable device manufacturer Garmin announced a partnership with Fitabase, integrating its consumer products with Fitabase’s data management platform to provide hardware support for clinical studies by tracking participants’ biometric data. This collaboration and API integration will offer researchers comprehensive access to data on activity, heart rate, sleep, and even pulse oximetry, facilitating a deeper understanding of the relationship between lifestyle and health outcomes, thereby accelerating digital health research and reducing patient costs.

Source: www.mobihealthnews.com

Pharmaceutical company Novo Nordisk has reached an agreement with Flex Digital Health, under which Novo Nordisk will utilize Flex’s BrightInsight platform to manage the connectivity and adherence of digital health devices. Earlier this month, Novo Nordisk announced the launch of two connected insulin pens—NovoPen 6 and NovoPen Echo Plus—to help patients track insulin usage, transmit data to their smartphones, and integrate with diabetes management platforms. Additionally, Novo Nordisk has established non-exclusive technical partnerships with Dexcom, Glooko, Roche, and IBM Watson Health, allowing their applications to work with the new devices to assist patients in managing diabetes data.

Source: www.mobihealthnews.com

On October 24, Vayyar Imaging, a company renowned for its 3D sensor imaging technology, launched a new product called Walabot Home. In response to the growing aging population and the fact that falls have become a major health risk for the elderly, Walabot Home uses low-power radio waves to detect user movements. If a fall is detected, it can automatically send out a distress signal. The device, which is about the size of a tablet, can be mounted on a wall. It does not use cameras, thereby addressing users' privacy concerns.

Source: www.mobihealthnews.com

The "2017-2018 Fitness Industry White Paper" shows that the number of gyms in China reached 71,003 in 2017-2018, with 18,703 new gyms added in the past year. The national growth rate of gyms was 27.74%, and the historical cumulative survival rate of gyms was 78%. In terms of gym revenue: the average monthly income for studios was 167,400 yuan, while clubs averaged 362,600 yuan per month. Studio members' annual accumulated spending was approximately 2.01 million yuan, whereas this figure for clubs was 4.35 million yuan. However, when looking at actual per capita annual consumption, studio members spent an average of 6,908 yuan annually, which is more than double the 3,016 yuan spent by club members. As of the end of May 2018, the average monthly growth rate of gyms/studios using heart rate monitoring systems over the previous 12 months was 20%.

Roland Berger believes that future healthcare system reforms will place greater emphasis on a people-centric approach, fostering service models driven by digitalization for population health management, integrated service networks, and the convergence of medical care, health insurance, and pharmaceuticals. China’s healthcare system will become value-oriented, ensuring that target populations receive appropriate medical and health services at the right time and in the right place. The service philosophy of high-end private hospitals has shifted from providing premium, convenient, and attentive disease diagnosis and treatment to offering continuous, full-lifecycle health management services covering prevention, diagnosis, treatment, rehabilitation, and nursing care for their target populations.

Starting from the definition, development background, and value of medical imaging clouds, this white paper conducts an in-depth analysis by combining the current development status and policy requirements. It elaborates in detail on the development pace, commercial opportunities, and network SLA requirements for five major application scenarios, and provides analytical recommendations on the rollout pace and trends of medical imaging cloud services. Finally, we hope this white paper can serve as a reference for industry research on medical imaging clouds and contribute to promoting the development of the medical cloud industry. Huawei iLab is committed to working with healthcare ecosystem partners and telecom operators to expand the industry and drive the development of medical imaging cloud services.